>>> Europe : Brokers & Downgrades - 23rd of May 2022 V2(+)

>>> Up
* BEWi Raised to Buy at Pareto Securities; PT 83 kroner
* Calida Raised to Buy at Research Partners; PT 65 Swiss francs
* Deutsche Bank Raised to Outperform at KBW; PT 14.80 euros
* DSV Raised to Buy at HSBC; PT 1,500 kroner
* Gjensidige Raised to Buy at HSBC; PT 230 kroner
* Kainos Raised to Buy at Canaccord; PT 1,350 pence (+)
* Kuehne + Nagel Raised to Buy at HSBC; PT 320 Swiss francs
* Shaftesbury Raised to Add at Numis; PT 640 pence
* TGS Raised to Hold at Kepler Cheuvreux; PT 155 kroner (+)
* Tryg Raised to Buy at HSBC; PT 185 kroner

>>> Down
* Capricorn Energy Cut to Neutral at JPMorgan; PT 243 pence
* Eli Lilly Reinstated Outperform at SVB; PT $341
* Equinor Cut to Hold at SocGen
* Hunting Cut to Neutral at JPMorgan; PT 310 pence
* Intertek Cut to Hold at Stifel; PT 5,500 pence
* Lululemon Cut to Neutral at KGI Securities; PT $271
* Marston's Cut to Hold at Stifel; PT 70 pence (+)
* Nokian Renkaat Cut to Sell at Stifel; PT 10 euros (+)
* Nike Cut to Neutral at KGI Securities; PT $106
* Publicis Cut to Underweight at Morgan Stanley; PT 48 euros
* Sanofi Reinstated Outperform at SVB; PT 121 euros
* WPP Cut to Underweight at Morgan Stanley; PT 850 pence

>>> Initiation
* Digital Value Rated New Buy at Intesa Sanpaolo; PT 122.50 euros (+)
* Disney Rated New Outperform at KGI Securities; PT $145 (+)
* Gilead Reinstated Market Perform at SVB; PT $68
* Siltronic Initiante at Underperform at BofA; PT €86 (+)

>>> Call
* Deutsche Bank Up to Outperform on Cheap Valuation, KBW Says
* Hunting and Capricorn Cut at JPM; Remains Positive on Oil Stocks (+)
* Kingfisher Share Buyback Should Be Well Received, RBC Says (+)
* Morgan Stanley’s Wilson Says Too Soon to Turn Bullish on Stocks (+)
* WPP, Publicis Cut at Morgan Stanley as Global Slowdown to Bite

>>> UCB - Announces data from two phase 3 Bimekizumab studies in psoriatic arthr

Announces data from two phase 3 Bimekizumab studies in psoriatic arthritis to be presented at EULAR 2022
- First presentations from the BE OPTIMAL and BE COMPLETE studies evaluating bimekizumab in the treatment of adults with active psoriatic arthritis who were biologic-naïve and TNF-inadequate responders, respectively
- A higher proportion of patients treated with bimekizumab vs. placebo achieved improvements in joint symptoms at week 16 as measured by ACR50, with a consistent clinical response across biologic-naïve (43.9% vs. 10.0%; p<0.001) and TNF-inadequate responder populations (43.4% vs. 6.8%; p<0.001)
- At week 16, a greater proportion of bimekizumab-treated patients achieved high levels of skin clearance, PASI90, vs. placebo, with a consistent clinical response across populations (61.3% vs. 2.9% for biologic naïve and 68.8% vs. 6.8% for TNF-inadequate responders; p<0.001 for each)
- At week 16, over 40% of bimekizumab-treated patients vs. placebo achieved minimal disease activity in both studies (p<0.001)
- The results will be presented at the European Congress of Rheumatology, EULAR 2022, in Copenhagen June 1st - June 4th.

>>> BMW : Reportedly exploring investments in solar, geothermal and hydrogen ene

Reportedly exploring investments in solar, geothermal and hydrogen energy to reduce dependence on natural gas - financial press
- The article cites comments from BMW production boss Milan Nedeljkovic, who said that the German auto industry would come to a standstill in the event of a halt to gas deliveries from Russia
- Nedeljkovic added that BMW is looking at where it can add solar panels to its plants, while it is also developing plans with local authorities to transport hydrogen to its plant in Leipzig, noting that hydrogen is very well-suited to lower or even fully compensate for gas demand
- Nedeljkovic further said that a new plant in Debrecen, Hungary, will rely heavily on solar, while BMW is also examining the use of geothermal energy

>>> NiCox : Nicox's lead candidate NCX-470 continues to advance in the Mont Blan

Nicox's lead candidate NCX-470 continues to advance in the Mont Blanc Phase III trial targeting the topical treatment of glaucoma, having recently reached 98% enrolment
- While Mont Blanc data are still expected in Q1 23, the company has recently pushed back the forecast completion timeline for Denali, the second Phase III trial, and we have thus postponed our NCX-470 launch expectation into H226 (from H225). Nicox's decision to advance NCX-4251 into dry eye disease (DED) significantly boosts the commercial prospects of this proprietary corticosteroid formulation, as over 30M people in the United States experience DED. We derive a risk-adjusted NPV (rNPV) valuation of €298M, up from €294M previously.
- We continue to apply a risk-adjusted net present value model with a 12.5% cost of capital. We obtain an rNPV of €298M, up from €294M previously, due to an increase in our NCX-4251 valuation, offset by the pushback in our NCX-470 US launch timing estimate and reduced Vyzulta net pricing estimates. After including €14.6M in Q122 net cash, we obtain an equity valuation of €312.4M or €7.23 per basic share (vs €7.44 previously). We model that Nicox's funds on hand should last through Q423 and that it will need to raise €104M (modelled as illustrative debt) before year-end 2026 (up from €45M previously) before launching NCX-470

>>> TradeGate Pre-Market Indications

DAX:
  • Delivery Hero (DHER TH) +3.3%
  • Infineon (IFX TH) +2.3%
  • Puma (PUM TH) +2.1%
  • Daimler Truck (DTG TH) +2%
  • Siemens (SIE TH) +1.9
  • HelloFresh (HFG TH) +1%
  • Bayer (BAYN TH) +1%
  • HeidelbergCement (HEI TH) +0.9%
  • Deutsche Telekom (DTE TH) +0.7%
  • Fresenius SE (FRE TH) +0.6%
MDAX:
  • Siemens Energy (ENR TH) +2.4%
    • Siemens Energy Says Gamesa Takeover to Speed Solving Challenges
  • ProSieben (PSM TH) +2.4%
  • RTL (RRTL TH) +2.3%
  • Bechtle (BC8 TH) +2.2%
  • Commerzbank (CBK TH) +2.1%
  • TeamViewer (TMV TH) +0.6%
  • Freenet (FNTN TH) +0.6%
SDAX:
  • VERBIO Vereinigte (VBK TH) +3.5%
  • Traton (8TRA TH) +2.9%
  • About You (YOU TH) +2.8%
  • Kloeckner (KCO TH) +2.4%
  • Jenoptik (JEN TH) +2.3%
  • ADVA Optical (ADVV TH) -2.3%
  • Adler Group (ADJ TH) -2.4%
    • Oaktree in Talks to Refinance Bonds Sold by Key Adler Backer

Business Of Fashion : Would You Buy a Mushroom Handbag?

Would You Buy a Mushroom Handbag?
For the first time, brands including Stella McCartney, Balenciaga and Hermès are bringing products made of mushroom-based materials to market, an early test for whether the next-generarion fabrics could one day hit the mainstream.
Stella McCartney's first bag made from the mushroom-based leather alternative Mylo launches in July. (Stella McCartney)


KEY INSIGHTS
  • After years of development, handbags, shoes and coats made from mushroom-based materials are hitting the market for the first time.
  • It’s an early test of whether the much-hyped innovation can compete with traditional leather and other alternatives.
  • For these materials to go mainstream, more work is needed to continue product development, scale up volumes and bring down prices.

Stella McCartney’s newest bag has taken four years to make it to the market.
Though its half-moon shape and chunky chain details reflect the brand’s signature Frayme style, the mini satchel is made of mycelium, the branching root structure of fungi that forms the base for a new generation of materials that are just making the leap from labs to store shelves.
The bag’s launch as a tight run of just 100 items in July is part of a flurry of highly limited debuts from brands ranging from Hermès to Lululemon that aim to test the market for a cohort of mycelium-based leather alternatives for the first time this year.
It’s a critical moment for a next-generation material that has attracted hundreds of millions of dollars of investment from brands and venture funds betting that growing consumer demand for vegan and less environmentally damaging products is set to disrupt the market for some of fashion’s highest-margin and valuable products.

The items coming to market now will be a gauge of both consumer appetite and product readiness as leading materials startups in the space prepare for wider commercialisation with the aim to eventually make mycelium-based items mainstream.
To succeed, the products need to be as good as leather, so “people won’t even see any compromise on … the touch or the feel or the wearability,” McCartney said during an interview in the light-filled atelier at her brand’s London headquarters. “Everyone’s trying to make this work. Everybody wants to make it work. But until it works, they’re not going to take a leap of faith. Because they’ve got something that currently works very well for them.”
A model walks the runway in Balenciaga's coat crafted from the mycelium-based material, Ephea. (Balenciaga)
The designer has been working on the challenge longer than most, first experimenting with Mylo, a material developed by California-based startup Bolt Threads, in 2018. The initial prototype was a museum piece — quite literally. The bag (a version of McCartney’s Falabella style) was displayed in London’s Victoria & Albert Museum as part of its “Fashioned from Nature” exhibition in 2018.
It was a groundbreaking glimpse at what might be possible, but it was far from market-ready. The material was brittle and cracked at the back, with a flaky, paper-like texture that was little like leather’s supple feel.
It took seven more iterations and years of close collaboration with the scientists at Bolt Threads and McCartney’s manufacturing partners to improve the material’s performance, quality and feel to a point where it was ready for sale. Early models had a sticky texture and were easily damaged. The quality of the material was inconsistent. And McCartney’s team had to figure out with its factories how to make products stick together because Mylo could not hold standard glues.
“I’m obviously a bit of a glutton for punishment,” McCartney said while contemplating a prototype of the first style set to make it to market, a structured matte black bag with a slightly pebbled texture. “Hopefully in the history of the fashion industry, this will be a mark that will be looked back on … like, ‘wow, this was the beginning, the first time we ever saw that,’ and now it’s mainstream.”
Demand for New Materials
Humans have been wearing clothing, bags and shoes made from animal skin for hundreds of thousands of years. Today, the global luxury industry thrives on leather goods — prized for their versatility, durability, aesthetic and links to powerful cultural archetypes from cowboys to rockers. The category made up around half of the roughly $100 billion in sales generated by Europe’s five largest luxury companies in 2020, according to equity analysts at Bernstein.

But the leather supply chain is also linked to animal cruelty and comes with significant environmental cost. Now, a rapid shift in consumer tastes towards products that live up to higher environmental and ethical standards is driving change. Other once highly valued fabrics like fur and exotic skins have already fallen from favour among some of luxury’s biggest players.
While leather is much more entrenched, its links to industrial cattle farming and polluting tanning processes also make it a particularly high-impact material that’s attracting mounting scrutiny. The potential for disruption is already playing out in associated sectors as plant-based meats and milk enjoy rapid growth, fuelled by a young consumer base concerned about both animal rights and the climate crisis.
Change has been slower to come to fashion, where (largely plastic) leather alternatives have historically been seen as cheaper, lower quality options that are difficult to position as more environmentally friendly. (It’s a challenge LVMH-backed McCartney is all too familiar with. Her refusal to use real leather in her collections was seen as a huge risk when she launched her brand with rival Kering (then Gucci Group) in 2001. And though she’s proven out the business case, the quest for real bio-based options is ongoing.
Interest is rapidly growing elsewhere, too. The market for innovative alternatives to animal skins is expected to be worth $2.2 billion by 2026, according to the nonprofit Material Innovation Initiative. Companies including Gucci- and Balenciaga-owner Kering, Prada and Hermès are experimenting with alternatives.
“There is an under-served segment of the market who want high quality, natural materials in line with their values. That is a segment the industry is very excited about,” said Matt Scullin, chief executive at MycoWorks, the California-based startup that convinced top-end leather goods powerhouse Hermès to break with tradition and experiment with its engineered mycelium. “That is where we stand to have the most impact in helping luxury brands grow in the near term and could be disruptive in the long term.”
Hopefully in the history of the fashion industry, this will be a mark that will be looked back on.
Materials made from mycelium’s branching webs have attracted particular interest. Compared to other next-generation alternatives, the process to grow sheets of interlacing mushroom roots is relatively mature, requires little energy or land and has a manufacturing process that is relatively easy to scale. That’s prompted a nearly unprecedented collaboration between brands, material science startups and manufacturers to get the technology to market.
Stella McCartney’s new bag is one product of an unusual consortium that also includes Kering, Adidas and Lululemon which have all committed to developing products using Mylo. Lululemon launched two bags with Mylo trims in February, while Adidas is aiming to roll out products within a year.
New York-based material science company Ecovative added Reformation and footwear company Wolverine to a group of brands working to commercialise its material last week. Meanwhile, Balenciaga’s Winter 2022 collection featured a dramatic full-length coat crafted from Ephea, a mycelium-based material developed by Italian manufacturer Sqim. Hermès said it expects to bring out items using MycoWorks’ engineered mycelium in the coming months.

“Mycelium materials are the best solution currently available for fashion products,” said Christian Tubito, director at Kering’s Material Innovation Lab. “It’s a little step when compared to other materials used for centuries in the fashion industry, but that little step is necessary in order to make a bigger one.”
Supply Chain Challenges
There are still significant challenges before mushroom materials make it to the mainstream.
Different materials have varying properties and qualities and aren’t all appropriate for the same applications. For instance, McCartney’s team found Mylo is still quite rigid meaning more development is needed for use in slouchy bag styles or ready-to-wear. The material also still requires plastic content to ensure quality, feel and durability, something the Bolt Threads team is actively working to reduce, chief executive Dan Widmaier said.
Hermès’ collaboration with MycoWorks was initially due to launch at the end of last year but still hasn’t hit the market. “This has not been about bringing something to market fast, it has been about bringing the right thing to market at the best possible quality that is scalable,” said Scullin.
And while companies are working to scale up production, volumes are currently limited and prices are high. McCartney’s Mylo Frayme bags are set to retail at £1,995 ($2,485). The brand’s most similar model currently for sale retails at £1,150. Adidas has held off rolling out products made from the material in part to ensure it can secure consistent quantities and quality of supply, said Paul Smith, the company’s senior director of innovation.
Lululemon released two bags trimmed with mycelium-based material Mylo in Februrary.
Efforts to resolve some of those kinks are already underway. MycoWorks is working to open a new facility that can produce millions of square feet of its engineered mycelium each year. Bolt Threads is in the process of scaling up a million square metre plant in the Netherlands, with plans to expand into the double-digit million square metre range within the next three years.
Though a square foot of Mylo currently costs around $30 per square foot, on par with top calf leather, which retails for around $25 to $40 a square foot, Widmaier said, with scale, it could come down to within the single-digit dollar range.
A New Status Symbol?
Perhaps just as important as the practical business challenges, the current moment is a test for whether consumers are ready to embrace mycelium as a luxury material.
Some, like Prada’s head of sustainability and marketing Lorenzo Bertelli, believe “the consumer is not ready.” The Milanese company is holding off on scaling up its experiments with leather alternatives, he told BoF in an interview earlier this month.
At Kering, it’s notable that the first brand to bring a mycelium-based product to market is Balenciaga, a label known for challenging fashion’s conventions and pushing social boundaries. But where Balenciaga goes, others often follow.
Lululemon’s initial Mylo products generated a strong consumer response globally, despite selling at a premium to the brand’s regular products, said chief product officer Sun Choe. The company is planning to roll out further products towards the end of next year. McCartney’s Frayme bags will go on wider release in 2023, with plans to also introduce a new colour.
“The true barometer at the end of the day will be the customer reaction — sales will be our final litmus test,” said Julie Gilhart, chief development officer at brand platform Tomorrow. “If the product has quality, style and is not more expensive than leather, then it’s a game-changer.”

WWD: Balenciaga Takes Crypto, the Rich’s Charities

Balenciaga Takes Crypto, the Rich’s Charities
Balenciaga will accept cryptocurrency in the U.S.

CRYPTO CRAZE: Was it because its show was at the New York Stock Exchange, or just customers wanting to pay with it? Regardless of the reason, Balenciaga revealed that it now is accepting payment in cryptocurrency. Given the plunge in their value over the last 10 days, one could argue the timing wasn’t ideal, but starting with the U.S., the brand will now accept crypto at its flagship stores, including on Madison Avenue in New York and Rodeo Drive in Beverly Hills, as well as on balenciaga.com. Other regions and e-commerce will follow, the company said.

The fashion house is still deciding what payment solutions provider it will use, but it will accept currencies like Bitcoin and Ethereum to begin with and other currencies will be added in due course.

As for the volatile fluctuations in value and whether that is cause for concern, the company said in a statement that, “Balenciaga is thinking long-term about crypto, and fluctuations in currency value are nothing new.”

The Kering-owned brand joins Tag Heuer in accepting crypto. The LVMH Moët Hennessy Louis Vuitton-owned watch brand earlier this month said its customers would be able to pay at checkout in one of 12 cryptocurrencies, including Bitcoin, Dogecoin and Ethereum through a solution provided by BitPay.